Plasma leucocyte elastase concentrations in smokers

C R K Hind, H Joyce, G A Tennent, M B Pepys, N B Pride

Abstract
The associations between cigarette smoking, plasma leucocyte elastase concentration, peripheral leucocyte count and FEV1 were examined in 148 men, 72 of whom were current cigarette smokers, 40 of whom were ex-smokers, and 36 who had never smoked. All men were part of a long-term survey. Smokers had significantly higher plasma leucocyte elastase concentrations than ex-smokers or those who had never smoked. Mean current FEV1 was lower, and the annual decline in FEV1 in the preceding 10 years was faster in smokers than the other two groups. A few smokers had slight increases in serum C-reactive protein concentrations. Although peripheral blood leucocyte counts were higher in smokers than in non-smokers or ex-smokers, no association was found in any of the three groups of men between plasma elastase concentration and peripheral leucocyte count, nor between either of these two variables and annual decline in FEV1, or current level of FEV1. There was also no relation between plasma elastase concentration and reported daily cigarette consumption or mixed expired carbon monoxide in smokers.

The results indicate that some male smokers have increased in vivo release of elastase from peripheral blood neutrophils at a time when there is no evidence of acute infection. Because leucocyte elastase is a strong candidate for pulmonary tissue damage, further studies of the mechanisms that increase plasma concentrations are indicated.

Cigarette smoking is a major risk factor for the development of progressive airflow obstruction and emphysema. There is considerable evidence that neutrophils may be important in mediating lung damage induced by smoking. Thus current smokers have higher circulating leucocyte counts and bronchoalveolar lavage (BAL) neutrophil counts than ex-smokers or non-smokers, and there is an inverse correlation between circulating leucocyte count and one second forced expiratory volume (FEV1) and forced vital capacity (FVC). In experimental studies in hamsters four hours' exposure to cigarette smoke causes extensive recruitment of leucocytes into the airway walls. Because elastase can cleave many structural and soluble proteins, numerous authors have postulated that it has an important role in the development of emphysema. In vitro release of elastase stored in the granules of polymorphonuclear leucocytes in response to stimuli such as zymosan is similar from the neutrophils of smokers and non-smokers; but incubation of neutrophils with cigarette smoke condensate results in increased in vitro release of elastase. Furthermore, increased in vitro elastase activity has been shown in cell-free BAL fluids of healthy smokers.

The availability of a simple procedure for the estimation of the human leucocyte elastase α1-proteinase inhibitor complex, the form in which the bulk of the released enzyme circulates in the plasma, facilitates further investigation of in vivo elastase release. Although one previous study found no differences between smokers and non-smokers in plasma leucocyte elastase concentrations, those studied were all healthy volunteers and their lung function was not measured. We measured plasma leucocyte elastase concentrations and circulating neutrophil counts in groups of cigarette smokers, ex-smokers and life-long non-smokers whose lung function had been prospectively documented over 10 years.

Methods
We studied 148 Caucasian men working in west London who were originally recruited in 1974 for a prospective study of lung function. All the selected men had consistent smoking habits as checked on several occasions by questionnaire and measurement of mixed expired carbon monoxide and plasma cotinine, the major metabolite of nicotine with an average elimination half-life of 20 hours. The men were divided into three groups: (1) 36 life-long non-smokers; (2) 40 ex-smokers who had stopped smoking seven or more years earlier; and (3) 72 current cigarette smokers. At the time of study 18 of these men smoked up to 15 cigarettes/day, 25 men smoked 16-25 cigarettes/day, and the remaining 29 men smoked more than 25 cigarettes/day. The mean ages of these subgroups all lay between 46-4 and 52-6 years (table). All men had a normal chest radiograph. None gave a history of asthma or other chest disease, although some had chronic cough and expectoration. Blood samples were only taken if the subject had had no symptoms of a respiratory or other infection in the preceding six weeks. The men were not asked to modify their smoking habits on the day of testing. On
### Smoking habit, peripheral blood leucocyte counts, plasma leucocyte elastase concentration and spirometry

<table>
<thead>
<tr>
<th>Smoking habit</th>
<th>No of subjects</th>
<th>Age (years)</th>
<th>Leucocyte count (× 10⁹/l)</th>
<th>Plasma elastase (µg/l)</th>
<th>FEV₁ (%) predicted</th>
<th>Δ FEV₁-year⁻¹ (ml·year⁻¹·m⁻³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smokers</td>
<td>36</td>
<td>46.4 (10.0)</td>
<td>6.58 (1.66)</td>
<td>98.7 (31.3)</td>
<td>115.6 (14.3)</td>
<td>4.40 (4.18)</td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>40</td>
<td>50.8 (10.9)</td>
<td>6.08 (1.11)</td>
<td>84.7 (37.1)</td>
<td>106.8 (15.7)</td>
<td>5.71 (4.48)</td>
</tr>
<tr>
<td>Current cigarette smokers ≤15/day</td>
<td>18</td>
<td>52.6 (6.8)</td>
<td>8.91 (2.84)</td>
<td>136.5 (62.8)</td>
<td>95.5 (18.8)</td>
<td>7.69 (4.73)</td>
</tr>
<tr>
<td>16–25/day</td>
<td>25</td>
<td>51.6 (9.6)</td>
<td>8.55 (2.16)</td>
<td>119.3 (58.1)</td>
<td>99.6 (14.9)</td>
<td>7.62 (5.90)</td>
</tr>
<tr>
<td>&gt;25/day</td>
<td>29</td>
<td>49.8 (12.9)</td>
<td>9.04 (2.01)</td>
<td>139.9 (85.1)</td>
<td>94.3 (20.0)</td>
<td>9.59 (7.00)</td>
</tr>
</tbody>
</table>

Values are mean (SD). * Δ FEV₁ = annual rate of decline in FEV₁ over preceding 10 years.

### Results

**LUNG FUNCTION**

Forced expiratory volume in one second (FEV₁) was measured using a dry bellows spirometer on the day of blood sampling and compared with predicted values. The current value was compared with the value obtained in the survey 10 years before and the annual decline in FEV₁ over this 10 year period calculated using the height-corrected difference in FEV₁ values (Δ FEV₁/year⁻¹ expressed as ml·m⁻³·year⁻¹).

Differences between the blood leucocyte counts and plasma elastase concentrations were determined by the Mann–Whitney U test (the non-parametric equivalent of the two sample t test). Correlations between different variables were examined using Spearman’s rank correlation coefficient.

**Effect of smoking habit on plasma elastase concentrations and leucocyte counts**

Mean plasma elastase concentration in smokers was significantly higher than in ex-smokers (p < 0.001) or non-smokers (p < 0.05), with some smokers showing greatly increased concentrations (table, figure). There was no significant difference in elastase concentration between non-smokers and ex-smokers (p = 0.056). As expected, the average number of blood leucocytes was also significantly higher in smokers than in non-smokers (table) (p < 0.001) or ex-smokers (p < 0.001), again with no significant differences between non-smokers and ex-smokers. Mixed expired carbon monoxide at the time of blood sampling was increased in smokers, averaging 7.6, 12.8, and 16.0 ppm in smokers who consumed ≤15, 15–25, and >25 cigarettes/day, respectively. In the smokers there was no correlation between the reported daily number of cigarettes smoked or mixed expired carbon monoxide and the increase in either the plasma elastase concentration or leucocyte count. There was no significant correlation in any of the three groups between the plasma elastase concentrations and leucocyte counts (smokers: r = 0.19; ex-smokers: r = 0.18; non-smokers: r = 0.09).

**Spirometry**

At the time of study, FEV₁ was significantly lower in smokers (table) than in non-smokers (p < 0.001) and ex-smokers (p = 0.001). Over the preceding 10 years, smokers had shown a significantly greater decline in height.
Smokers. Note that and 451 Plasma are off-scale values in smokers in 234 itg/l, respectively.

There were no significant correlations between plasma elastase concentration or leukocyte count and current FEV1 or annual decline in FEV1 in any of the three groups of men (all p values > 0.3).

Discussion
In this study we found that on average cigarette smokers had a significantly higher circulating concentration of leukocyte elastase than either non-smokers or ex-smokers. This increase could not be accounted for by the presence of a coincident infectious disease, because serum C-reactive protein was normal in most subjects.

We took care to handle the blood specimens so as to avoid in vitro release of elastase from white cells; others have shown that plasma elastase values remain stable in vitro over one hour, provided coagulation is avoided. Furthermore, we found no correlation between the plasma elastase concentration and peripheral leukocyte count in smokers, even although, as previously shown by several groups, their leukocyte count was also raised. We aimed to study typical diurnal values in our subjects and made no attempt to control their preceding smoking history, although details of this were obtained for the hours before venesection. Although diurnal variation in plasma elastase has not been shown, rises in plasma elastase in an individual smoker have been shown after a period of particularly intense smoking, which is also associated with an acute rise in blood neutrophil counts. In our study, however, there was no relation between mixed expired carbon monoxide, a marker of the recent smoking history, and plasma elastase concentrations. None of the smokers with expired carbon monoxide of > 20 ppm had elastase concentrations above 160 μg/l; the 15 highest values of elastase were found in smokers whose expired carbon monoxide was less than 17 ppm. The mechanism of increase in the neutrophil count in smokers is not known, though a significant relation between the peripheral leukocyte count and the plasma nicotine concentration has been reported.

Similarly, no correlation was found between the plasma elastase concentration or leukocyte count and abnormalities in lung function (as assessed by annual change in FEV1 over the preceding 10 years, or current percentage predicted FEV1). Although few of the men had values of FEV1 definitely below the normal range, annual decline of FEV1 in the preceding years had been faster in the smokers than in non-smokers.

The finding of increased circulating leukocyte elastase in some smokers may be relevant to the induction of lung damage caused by smoking which is known to vary greatly among smokers. Activated neutrophils act both as effector cells of tissue damage and as amplifiers of the inflammatory process. Their azurophil granules contain a spectrum of proteinases capable of degrading the structural components of the interstitium—elastin, collagen, proteoglycans and basement membranes. The generation of free radicals by these cells may also cause tissue damage either directly by lipid peroxidation, or indirectly by inactivation of the enzymes that normally protect against proteolytic damage, such as α1-proteinase inhibitor, antileucoprotease. Cigarette smoke itself may induce an elastase-α1-proteinase imbalance by directly inactivating elastase inhibitors. Thus Weitz et al recently reported a large increase in fibrinopeptide A—α1-1-21 in the peripheral blood of cigarette smokers compared with non-smokers. Because this fibrinogen-derived peptide is apparently only cleaved by human neutrophil elastase, these authors used concentration of this peptide for another assay of in vivo release of neutrophil elastase into the plasma. Bridges et al found increases in myeloperoxidase activity within peripheral blood neutrophils in young male smokers compared with non-smoking controls; in these studies increased myeloperoxidase activity was not related to numbers of peripheral blood neutrophils, current lung function, or number of cigarettes smoked. Superoxide production by peripheral blood neutrophils was increased in smokers compared with non-smokers and superoxide production by blood leukocytes has been related to the degree of bronchial hyperresponsiveness in those with chronic airways obstruction. Although there was no relation between plasma elastase concentrations and the degree of abnormality in lung function in any of the groups we studied, the site of tissue damage and potential release of elastase is the lung interstitium; we have investigated only the peripheral blood. Further studies are required to establish the clinical importance of the present findings for the development of lung tissue damage in smokers.

This work was supported by a grant from the Medical Research Council (G84040575A).
Plasma leucocyte elastase in smokers